Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20562544 | 0.86 | CSNK2A1 (0.34) | CSNK2A1HTR1DHTR1B | |
| SCHEMBL16070128 | 0.86 | HTR1D (0.33) | HTR1DHTR1B | |
| SCHEMBL31292374 | 0.86 | CSNK2A1 (0.34) | CSNK2A1HTR1DHTR1B | |
| SCHEMBL20562529 | 0.85 | ALDH1A1 (0.33) | CSNK2A1HTR1DHTR1B | |
| SCHEMBL1022724 | 0.81 | ATM (0.38) | HTR1DHTR1BGAAATM | |
| SCHEMBL28605284 | 0.81 | CSNK2A1 (0.38) | CSNK2A1GAA | |
| SCHEMBL7979651 | 0.78 | ADRA2A (0.40) | HTR1DHTR1B | |
| SCHEMBL954302 | 0.77 | HTT (0.32) | CSNK2A1GAAATM | |
| SCHEMBL11860918 | 0.77 | CYP3A4 (0.41) | GAAATM | |
| SCHEMBL5728741 | 0.77 | CYP2A6 (0.33) | CSNK2A1GAAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112805005-B | Thyroxine receptor beta agonist compounds | 拓臻股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-3840755-B1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025224262-A1 | COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| EP-4608816-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | Monte Rosa Therapeutics AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-21 | — | — | US | disclosed |
| US-20250236615-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2025-07-24 | — | — | US | disclosed |
| WO-2024260309-A1 | THR-β RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, AND USE METHOD THEREFOR | 西威埃医药技术（上海）有限公司 | 2024-12-26 | — | — | WO | disclosed |
| CN-118290483-A | Pyridazinone compound and application thereof | 烟台药物研究所 | 2024-07-05 | — | — | CN | disclosed |
| WO-2024092039-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| EP-3625222-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | disclosed |
| WO-2020041741-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2020-02-27 | — | — | US | disclosed |
| CN-110612296-A | Phenyl derivatives as PGE2 receptor modulators | 爱杜西亚药品有限公司 | 2019-12-24 | — | — | CN | disclosed |
| WO-2018210994-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
| US-6288101-B1 | ADMINISTERING COMPOUNDS SUCH AS 2,6-DIMETHYL-4-ISOPROPYLBENZALDEHYDE TO TREAT INDICATIONS WHERE STIMULATION OF SUBTYPES OF THE SEROTONIN RECEPTOR IS IMPLICATED, SUCH AS MIGRAINES | VIRGINIA COMMONWEALTH UNIVERSITY | 2001-09-11 | — | — | US | disclosed |
| US-6124338-A | TREATING MIGRAINE HEADACHE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-09-26 | — | — | US | disclosed |
| US-6048862-A | Benzylamidine derivatives with serotonin receptor binding activity | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-04-11 | — | — | US | disclosed |
| US-5969137-A | TREATMENT OF NERVOUS SYSTEM DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1999-10-19 | — | — | US | disclosed |
| WO-1998012183-A1 | IMIDAZOLES WITH SEROTONIN RECEPTOR BINDING ACTIVITY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1998-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | CSNK2A1 1679/4885HTR1D 236/4885HTR1B 153/4885 |
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | CSNK2A1 1203/4885HTR1D 198/4885HTR1B 168/4885 |
| US-20250236615-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | CSNK2A1 1679/4885HTR1D 236/4885HTR1B 153/4885 |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | CSNK2A1 172/4885HTR1D 4379/4885HTR1B 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.